Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PITUITARY NEOPLASMS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMedDate not supplied

[Pituitary neoplasms extending into the nasal cavity and their needle biopsy cytodiagnosis].

In 5.5% of 126 patients treated for hypophyseal tumors at the Burdenko Institute of Neurosurgery, AMS USSR for 12 months, spread of the new growth to the nasal cavity was revealed. The tumor was usually located in the posterosuperior parts of the nose and was discovered on anterior rhinoscopy only after the nasal mucosa had been carefully anemized, particularly with the use of a nasal dilator with a lamp on its end specially designed by us. Spread of a hypophyseal tumor to the nasal cavity was encountered when the tumor was very large and grew regularly in all directions or when it was marked by selective infrasellarg growth in the direction of the sphenoidal sinus. Cytologic examination of the punctate made it possible to determine the presence of the hypophyseal tumor and its character (benign, malignant) and differentiate it from other new growths and from c.s.p. cysts.

Adenocarcinoma↗
PubMed1977

[Functional histopathology of pituitary neoplasms (author's transl)].

The generally accepted classification of pituitary adenomas into eosinophilic, basophilic, mixed, and chromophobe types has not been very useful since no clear correlation exists between the staining character of the tumor cells and the clinical syndrome produced. The ultrastructural examination of different adenoma types with clinically manifest endocrine activity (acromegaly, amenorrhea-galactorrhea-syndrome, Cushing's disease) shows that the type of hormone secreted can only be determined in few cases. The ultrastructure is more representative of the activity of the secretory process than of the type of the product. Histoimmunological methods achieve the specific identification of the various types of adenomas with endocrine symptomatology. The so-called "chromophobe" adenomas, which only manifest signs of a space occupying lesion with pituitary insufficiency of varying degree and compression of the visual pathways, represent a mixed group. The majority of the cases (about 60%) shows increased prolactin secretion with amenorrhea or loss of potency, but without galactorrhea or gynecomastia. A small group of cases may either produce normal hormones (growth hormone or prolactin) at a very low rate, or secrete hormone fragments or abnormal, as yet undeterminable substances. The oncocytomas, which stain with eosin in light microscopy, seem to suffer from a defective metabolism and therefore may have lost the ability of hormone production.

Adenoma↗
PubMed2001

[Somatostatin analogs in the clinical management of pituitary neoplasms].

The medical approach to patients with secreting or clinically non-functioning pituitary adenoma as made considerable progress thanks to the use of new somatostatin analogs. They were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in GH concentration in over 90% of acromegalic patients. Good results were obtained using slow-release analog treatment also in TSH-secreting adenomas, whereas the therapeutic efficacy of these peptides in clinically non-functioning adenomas is still controversial. Treatment with somatostatin analogs improves symptoms, normalises hormone secretion and in some cases may induce a reduction in the volume of pituitary adenomas. Scintigraphy with octreotide may help to select patients who respond to this form of treatment.

Acromegaly↗